To maximize comparability, the eligibility criteria for the participants from MagnetisMM-5 trial will be applied to patients from the RWD source, as feasible.
Inclusion Criteria:
- Male or Female aged 18 years and older at index date
- Diagnosis of MM
- Measurable disease according to IMWG criteria
- Prior anti-MM therapy (1-3 prior lines of therapy)
- ECOG performance status ≤2
Exclusion Criteria:
- Acute plasma cell leukemia
- Amyloidosis
- Smoldering MM
- Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)
- Ongoing Grade 2 or higher peripheral sensory or motor neuropathy.
- Active systemic infection or SARS-CoV-2 viral infection
- Active malignancy within 3 years before index, except for basal cell or squamous cell skin cancer or carcinoma in situ
- Other surgical, medical, or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
- Previous treatment with a BCMA-directed therapy or a CD3-redirecting therapy.
- Anti-CD38-directed therapy within 6 months preceding the first dose of treatment in this study
- Refractory to prior anti-CD38-directed therapy (disease progression while on or within 60 days of the last dose of any anti-CD38-directed therapy or failure to achieve at least MR).
- Previous pomalidomide therapy
- Administration with an investigational drug within 30 days prior to index
- For women of childbearing potential: Pregnancy test positive at screening
